An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: As monotherapy, for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Nov.
Tebentafusp (Kimmtrak): CADTH Reimbursement Recommendation: Indication: For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jan.
Melanoma: assessment and management.
London: National Institute for Health and Care Excellence (NICE); 2022 Jul 27. (NICE Guideline, No. 14.)
Pancreatic cancer in adults: diagnosis and management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2018 Feb. (NICE Guideline, No. 85.)
Addendum to Clinical Guideline 164, Familial breast cancer.
London: National Institute for Health and Care Excellence (NICE); 2017 Mar. (Clinical Guideline Addendum, No. 164.1.)
Suspected cancer: recognition and referral.
London: National Institute for Health and Care Excellence (NICE); 2023 Oct 24. (NICE Guideline, No. 12.)
Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation.
Geneva: World Health Organization; 2012.
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Setmelanotide (Imcivree): CADTH Reimbursement Recommendation: Indication: For weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Nivolumab (Opdivo): CADTH Reimbursement Recommendation: Indication: As a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC [Internet].
Psoriasis: assessment and management.
London: National Institute for Health and Care Excellence (NICE); 2017 Sep 1. (NICE Clinical Guidelines, No. 153.)
Addendum to Haematological Cancers: improving outcomes (update).
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Special Topics in Venous Thromboembolism [Internet].
Grant PJ, Courey AJ, Hanigan S, et al.
Ann Arbor (MI): Michigan Medicine University of Michigan; 2019 Feb.
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on